To evaluate the possible use of mutant ras as a biomarker for lung cancer, we have analyzed "normal appearing" lung tissue, lung tumor, lung metastases and sputum samples from patients with non-small cell lung cancer (NSCLC). As a control, we used lung tissue and sputum samples from patients without
Detection of K-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis
β Scribed by Phouthone Keohavong; Wei-Min Gao; Kui-Cheng Zheng; Hussam Mady; Qing Lan; Mona Melhem; Judy Mumford
- Book ID
- 108047608
- Publisher
- Elsevier Science
- Year
- 2004
- Tongue
- English
- Weight
- 157 KB
- Volume
- 324
- Category
- Article
- ISSN
- 0003-2697
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Gene mutations in __APC__, __Kβras__, and __p53__ are thought to be essential events for colorectal cancer development. Recent data seem to indicate that __Kβras__ and __p53__ mutations rarely coβexist in the same tumor, indicating that these alterations do not represent a synergistic e
Mutations in codon I 2 of K-ras occur in a high proportion of pancreatic cancer cases. Although there is evidence that p53 mutations also occur in this tumor, few studies have been reported to date and no comparison has been made of K-ras and p53 mutations in the same tissues. Single-strand conforma
## Abstract Our previous study showed a characteristic p53 mutational spectrum in lung tumors from lung cancer patients in the Western Pennsylvania region. To further understand the involvement of p53 mutations in lung tumor development, in this study we compared p53 mutational spectra and distribu